Skip to content

Research on Clinical Practice for Generalized Anxiety Disorder (GAD) Using the General Public as Subjects

Research on Clinical Practice for Generalized Anxiety Disorder (GAD) Using the General Public as Subjects - Research on Clinical Practice for Generalized Anxiety Disorder (GAD) Using the General Public as Subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000049573
Enrollment
20000
Registered
2022-11-21
Start date
2022-12-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized anxiety disorder

Interventions

None listed

Sponsors

Viatris Pharmaceuticals Japan Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Respondents must agree to participate in the research. 2.Respondents must be of age 18 or older at the time of expressing consent to participate in this study

Exclusion criteria

Exclusion criteria: There are no exclusion criteria for this study.

Design outcomes

Secondary

MeasureTime frame
1.EQ-5D-5L scores in the population of GAD-7 scores 10 or higher vs. the rest, and differences in such scores between the two populations. 2.Status of medical institution visitations in the population of GAD-7 scores 10 or higher. 3.Status of disease recognition in the population of GAD-7 scores 10 or higher.

Primary

MeasureTime frame
Percentage of patients of GAD-7 scores 10 or higher among the total population in this study.

Countries

Japan

Contacts

Public ContactHaruhiko Seki

INTAGE Healthcare Marketing Insight Division Healthcare Research Department 1

haruhiko.seki@intage.com03-5295-1579

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026